Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker

Clinical Editorial

British Journal of Cancer, Published online: 09 April 2026; doi:10.1038/s41416-026-03394-1 Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

BMJ OpenRelated by Conditionmelanoma

Emotional distress and immune checkpoint inhibitor efficacy in hepatocellular carcinoma: multicent

Oncology • 22 Jul 2026

medRxivRelated by Conditionmelanoma

Real-world systemic therapy use and survival in synchronous metastatic solid cancers: nationwide a

Oncology • 21 Jul 2026

ClinicalTrialsRelated by Conditionmelanoma

Pilot Study of Spatially Fractionated Radiation Therapy in Extra-Cranial Soft Tissue Metastases

Oncology • 30 Mar 2026

ClinicalTrialsRelated by Conditionmelanoma

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Oncology • 19 Feb 2026

BMJ OpenRelated by Conditionmelanoma

Updating GRRAS: Methods Review Protocol for Reliability, Agreement and Measurement Error Studies

General • 22 Jul 2026

Br J CancerRelated by Conditionmelanoma

Hepatic metastasis surveillance in uveal melanoma: a retrospective cohort study from a UK tertiary centre (2006–2022)

Oncology • 16 Apr 2026